These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 32456316)

  • 1. γδ T Cells: The Ideal Tool for Cancer Immunotherapy.
    Yazdanifar M; Barbarito G; Bertaina A; Airoldi I
    Cells; 2020 May; 9(5):. PubMed ID: 32456316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
    Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
    Front Immunol; 2019; 10():2717. PubMed ID: 31824502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic β-Adrenergic Receptor Activation Augments the
    Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
    Front Immunol; 2019; 10():3082. PubMed ID: 32038628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
    Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
    Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Function of γδ T cells in tumor immunology and their application to cancer therapy.
    Park JH; Lee HK
    Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing γδ T cells in anticancer immunotherapy.
    Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L
    Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.
    Correia DV; d'Orey F; Cardoso BA; Lança T; Grosso AR; deBarros A; Martins LR; Barata JT; Silva-Santos B
    PLoS One; 2009 May; 4(5):e5657. PubMed ID: 19479075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
    Gomes AQ; Martins DS; Silva-Santos B
    Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of γδ T cells in cancer immunotherapy.
    Nussbaumer O; Koslowski M
    Immunooncol Technol; 2019 Jul; 1():3-10. PubMed ID: 35755322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. γδ T-cell immunotherapy for lung cancer.
    Yoshida Y; Nakajima J; Wada H; Kakimi K
    Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
    Park JA; Santich BH; Xu H; Lum LG; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.
    Zhou J; Kang N; Cui L; Ba D; He W
    Cell Mol Immunol; 2012 Jan; 9(1):34-44. PubMed ID: 21666706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
    Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
    Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A close look at current γδ T-cell immunotherapy.
    Ma L; Feng Y; Zhou Z
    Front Immunol; 2023; 14():1140623. PubMed ID: 37063836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. γδ T Cell-Based Adoptive Cell Therapies Against Solid Epithelial Tumors.
    Bustos X; Snedal S; Tordesillas L; Pelle E; Abate-Daga D
    Cancer J; 2022 Jul-Aug 01; 28(4):270-277. PubMed ID: 35880936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What lessons can be learned from γδ T cell-based cancer immunotherapy trials?
    Fournié JJ; Sicard H; Poupot M; Bezombes C; Blanc A; Romagné F; Ysebaert L; Laurent G
    Cell Mol Immunol; 2013 Jan; 10(1):35-41. PubMed ID: 23241899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside.
    Gogoi D; Chiplunkar SV
    Indian J Med Res; 2013 Nov; 138(5):755-61. PubMed ID: 24434328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. γδ cell-based immunotherapy for cancer.
    Lo Presti E; Corsale AM; Dieli F; Meraviglia S
    Expert Opin Biol Ther; 2019 Sep; 19(9):887-895. PubMed ID: 31220420
    [No Abstract]   [Full Text] [Related]  

  • 20. γδ T cells and their potential for immunotherapy.
    Wu YL; Ding YP; Tanaka Y; Shen LW; Wei CH; Minato N; Zhang W
    Int J Biol Sci; 2014; 10(2):119-35. PubMed ID: 24520210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.